ThromboGenics - QuickView



21 March 2012

Event

Alcon deal for ocriplasmin

Investment summary: Vision to deliver

Securing Alcon (Novartis) as an ex US partner for eye drug ocriplasmin is a significant milestone in ThromboGenics' path to becoming a fully-integrated pharmaceutical company. Shares in the Belgian company have gained 9% since the deal and now trade at record highs. With burgeoning expectations comes increasing pressure to deliver. The Alcon deal, with €165m in near-term payments, provides ocriplasmin with the best possible start in Europe and lends significant financial support to ThromboGenics' own launch plans in the US.

Partner of choice

Alcon, acquired by Novartis in 2010 for \$51bn, is a global leader in the eye care market and emerged the winner from a competitive partnering process. Alcon is paying €75m upfront and €90m upon European approval and launch, expected by Q113. Further milestones up to €210m are possible on successful development of ocriplasmin for new indications, as well as estimated 25% royalties on net sales.

Retaining US interests

US partnering rights were "never on the table", emphasising ThromboGenics' desire to build commercial infrastructure; a US HQ recently opened in New Jersey. BLA filing under priority review is expected by end April 2012, an FDA advisory committee review is likely in early H212 with US launch due in Q113.

Pipeline in a product


Ocriplasmin, a truncated form of human plasmin, is injected into the eye to treat vitreomacular adhesion (VMA), a serious cause of vision distortion and blindness. An estimated 500,000 patients have VMA in the US and the five biggest EU markets. The pan-EU market opportunity is estimated at €600m based on 300,000 VMA patients at €2,000 per treatment with ocriplasmin. Further studies are ongoing in retinal vein occlusion, diabetic macular oedema and age-related macular degeneration (AMD). Phase II data in AMD are due H212 and ocriplasmin could be a complementary therapy to Lucentis/Eylea; 30% of AMD patients have VMA.

Valuation: Fair EV of €650m

Based on estimated latest cash of €155m (including €75m deal upfront),
ThromboGenics' EV of €650m seems fair while offering upside upon regulatory
approvals and successful commercial launches of ocriplasmin.

Consensus estimates (pre Alcon deal)						
Year End	Revenue (€m)	PBT (€m)	EPS (€)	DPS (€)	P/E (x)	Yield (%)
12/10 12/11	6.18 2.48	(13.9) (21.6)	(0.47) (0.67)	0.0	N/A N/A	N/A N/A
12/12e	4.90	(33.5)	(1.03)	0.0	N/A	N/A N/A
12/13e	35.5	(4.77)	0.14	0.0	N/A	

Price €24.85
Market Cap €805m



Code THR
Listing Euronext, Brussels
Sector Biotechnology
Shares in issue 32.4m

Business

ThromboGenics is a Belgian biopharmaceutical company focused on developing and commercialising the eye drug ocriplasmin; EU (via Alcon) and US launches are due in Q113. Antibody candidates targeting cardiovascular disorders and cancer are in mid-stage clinical trials.

Bull

- Ocriplasmin close to US/EU approval as first drug treatment for VMA.
- Alcon to commercialise ex. US and pay significant milestones and royalties.
- 100% of US profits retained.

Bear

- US commercialisation of ocriplasmin still likely to require fresh funds.
- Significant development costs remain through 50:50 cost share with Alcon.
- EU and US reimbursement hurdles likely to slow product uptake.

Analysts

Christian Glennie +44 (0)20 3077 5727 Robin Davison +44 (0)20 3077 5737

healthcare@edisoninvestmentresearch.co.uk

EDISON QUICKVIEWS ARE NORMALLY ONE OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.

EDISON INVESTMENT RESEARCH LIMITED

EDISON INVESTMENT RESEARCH LIMITED Edison Investment research company. It has won industry recognition, with awards in the UK and internationally. The team of 80 includes over 50 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 350 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison's research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584).

DISCLAIMER

DISCLAIMER
Copyright 2012 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison Investment Research Limited for publication in the United Kingdom. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison Investment Research Limited at the time of publication. The research in this document is intended for professional advisers in the United Kingdom for use in their roles as advisers. It is not intended for retail investors. This is not a solicitation or inducement to buy, sell, subscribe, or underwrite securities or units. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment. A marketing communication under FSA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment Research Limited has a restrictive policy relating to personal dealing. Edison Investment Research Limited is authorised and regulated by the Financial Services Authority for the conduct of investment business. The company does not hold any positions in the securities mentioned in this report. However, its directors, officers, employees and contractors may have a position in any or related securities mentioned in this report. Edison Investment Research Limited or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mention

Edison Investment Research